Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
28 489 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

XXXXXXXX XXXXXX X XXXXXXXXX PRAVOMOCI (EU) 2020/1182

xx xxx 19. xxxxxx 2020,

kterým xx xxx xxxxx přizpůsobení xxxxxxxxxxx a xxxxxxxxx xxxxxxx xxxx xxxx 3 přílohy XX xxxxxxxx Evropského xxxxxxxxxx x Xxxx (ES) x. 1272/2008 x xxxxxxxxxxx, xxxxxxxxxx a xxxxxx xxxxx x xxxxx

(Xxxx s xxxxxxxx xxx XXX)

XXXXXXXX XXXXXX,

x xxxxxxx xx Xxxxxxx x xxxxxxxxx Evropské xxxx,

x xxxxxxx xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (XX) x. 1272/2008 ze xxx 16. xxxxxxxx 2008 x klasifikaci, xxxxxxxxxx a balení xxxxx x xxxxx, x xxxxx x xxxxxxx směrnic 67/548/EHS x 1999/45/ES a x xxxxx xxxxxxxx (XX) č. 1907/2006&xxxx;(1), x xxxxxxx xx xx. 37 xxxx. 5 uvedeného nařízení,

vzhledem x těmto důvodům:

(1)

Tabulka 3 x části 3 xxxxxxx XX xxxxxxxx (ES) x. 1272/2008 obsahuje seznam xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx nebezpečných látek xx xxxxxxx xxxxxxxx xxxxxxxxxxx x xxxxxxx 2 xx 5 xxxxxxx X xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx agentuře xxx xxxxxxxx xxxxx („agentura“) xxxx x xxxxxxx x článkem 37 xxxxxxxx (XX) č. 1272/2008 předloženy návrhy xx xxxxxxxx harmonizované xxxxxxxxxxx a xxxxxxxx xxxxxxxxx xxxxx x xxxxxxxxxxx xxxx zrušení xxxxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx některých xxxxxx xxxxx. Na xxxxxxx xxxxxxxxxx&xxxx;(2) x xxxxx xxxxxxx, xxxxx xxxxx Xxxxx xxx xxxxxxxxxx xxxxx („RAC“) agentury, xxxxx x xxxxxxxxxx xxxxxxxxxxxx xxxxx, xx xxxxxx zavést, aktualizovat xx xxxxxx harmonizované xxxxxxxxxxx a označení xxxxxxxxx xxxxx. Xxxxxxx xxxxxxxxxx xxxxxx XXX xxxx:

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx kyseliny xxxxxxx... %[X ≤ 70 %],

—

xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx xxxxxx x xxxxxxx křemíku (x xxxxxxx &xx; 3 μx,xxxxx > 5 μx x poměru xxxxx ≥ 3:1),

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxx(xxxxx)xxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxxx, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx dimethyl-disulfidu,

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxx xxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxx (N-hydroxy-N-nitrosocyklohexylaminato-O,O’)-mědi, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Cu-HDO],

—

stanovisko xx xxx 14. září 2018 ohledně dioktyltin-dilaurátu, [1] xxxxxxxx, dioktyl-, xxx(xxxx xxxxxxx) derivátů [2],

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxxxxxx[xxx,x]xxxxxxxx, xxxxxxx[x,x]xxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxx (XXX), (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyklopentanolu,

—

stanovisko xx dne 8. xxxxxx 2018 xxxxxxx xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxx (XXX), (2RS,3RS)-1-(4-chlorofenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-olu,

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx 2,2-bis(brommethyl)propan-1,3-diolu,

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx, (2E)-3,7-dimethylokta-2,6-dien-1-olu,

—

stanovisko ze xxx 28. xxxxx 2019 xxxxxxx 2-(4-terc-butylbenzyl)propionaldehydu,

—

stanovisko xx dne 9. xxxxxx 2018 xxxxxxx XXXX-xxxxxxxxxx (ISO), S-ethyl (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, flupyradifuronu,

—

stanovisko xx dne 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxxx-xxxxxxx (XXX), methyl 4- [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)karbonylsulfamoyl]-5-methylthiofen-3-karboxylátu,

—

stanovisko ze xxx 9. xxxxxx 2018 xxxxxxx X-(+)-xxxxxx xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx xx dne 8. června 2018 xxxxxxx glyoxylové xxxxxxxx …%,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx natrium-N-(hydroxymethyl)glycinátu, [xxxxxxxxxxx xxxxxxxx z xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx (xxxxx-XXX-xxxxx)xxxxxxxxxxx draselného, xxxxxxxxxx(xxxxxxx)xxxxxx-1-xxxxx, xxxxxxxx xxxx, [K-HDO],

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, N-ethyl-N,N-dimethylhexadekan-1-aminium-ethyl-sulfátu, xxxxxxxxxxx-xxxxx-xxxxxxx [XXX],

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx (2RS)-2-[4-(4-chlorfenoxy)-2(trifluoromethyl)fenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-olu, mefentriflukonazolu,

—

stanovisko xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 ohledně xxxxxxxxx-xxxxx, (T-4)-bis[1-(hydroxy-kappa-O)pyridin-2(1H)-thionát-kappa-S]zinku,

—

stanovisko ze xxx 30. xxxxxxxxx 2018 xxxxxxx 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xxx, xxxxxxxxxxxxxxx (XXX),

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx 4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXXXX],

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx 2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xxx, [XXXX],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, fluxapyroxadu,

—

stanovisko xx xxx 8. června 2018 xxxxxxx X-(xxxxxxxxxxxxx)xxxxxxxxxx, xxxxxxxxxxxxxxxxxx, [XXX],

—

xxxxxxxxxx ze xxx 15. října 2018 ohledně 5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxxx, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx iprovalikarbu (XXX), isopropyl [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), X-xxxxx-4,5-xxxxxxxx-2(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxx, výtažku [xxxx xxxxxxxx za studena xx semen xxxxxxxx Xxxxxxxxxxx xxxxxx bez xxxxxxxx, xxxxxxxxxxx superkritickým xxxxxx xxxxxxxxx],

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx kyseliny xxxxxxx …%[C> 70 %],

—

xxxxxxxxxx x 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [D4],

—

stanovisko xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxx-xxxxxxx (XXX), X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx 30. xxxxxxxxx 2018 xxxxxxx fosfinu,

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx dichlordioktylstannanu,

—

stanovisko xx dne 30. xxxxxxxxx 2018 xxxxxxx 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [DOTE],

—

stanovisko xx xxx 30. listopadu 2018 xxxxxxx olova,

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx x-xxx(2,3-xxxxxxxxxxxx)xxxxxxx, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx ze dne 14. xxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (XXX), xxxxxx 2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně xxxxxxxxxxxxx (XXX), methyl (E)-2-{2-[6-(2-kyanofenoxy)pyrimidin-4-yloxy]fenyl}-3-methoxyakrylátu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (ISO), (XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 ohledně 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx ze dne 14. xxxx 2018 xxxxxxx mesotrionu (XXX), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx okthilinonu (ISO), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXX],

—

xxxxxxxxxx ze xxx 14. září 2018 xxxxxxx hymexazolu (XXX), 3-xxxxxxx-5-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxx (XXX), xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), reakční xxxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthematu,

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx-xxxxx, xxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,

—

xxxxxxxxxx ze xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxxx hexyl 2-(1-(xxxxxxxxxxxxxxxxxxxxxxxx) xxxxxxxxx)xxxxxxxx, xxxxx 2-[4-(xxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx.

(3)

Xxxxx xxx x xxxxx xxxxx (xxxxx XXX 7439–92–1 x xxxxxxxx xxxxx 082–013–00–1 (olovo x prášku; [průměr xxxxxx &xx; 1 xx];) a 082–014–00–7 (xxxxxxxx xxxxx; [průměr xxxxxx ≥ 1 xx];)), RAC xx xxxx stanovisku xx xxx 30. listopadu 2018 xxxxxx použít xxxxxxx xxxxxxxxxxxxxxx klasifikaci xx xxxxxxxxx x xxxxxxxxx xxxxx. Xxxxx xxxxxxxx x xxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx, tvárné struktuře xxxxx, ke xxxxxxxxxx xxxxxxx xxxxxx xxxxxx x vzhledem x xxxxx xxxxxxxxxxxxxxx klasifikaci x celistvých x xxxxxxxxxx xxxxx jiných xxxx x xxxxxxxxxxxx xxxxxxxxx x xxxxxxx XX musí XXX xxxxxxx xxxxx xxxxxxxxx xxxx, xxx xx xxx xx xxxxxxxxx x xxxxxxxxx xxxxx xxxxx xxxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx. Xxxxx xxxx xxxx xxxxxxxxxx xxxx xxxxxxx poznatky, x xxxxx vyplývá, xx xxxxxxxxxxxxxxx klasifikace xxx celistvou xxxxx, xxx xx doporučilo xxxxxxxxxx xxxxxx XXX, xxxxxx být xxxxxx. Xxxxxxxxxxxxxxx xxxxxxxxxxx pro xxxxxxxxx formu xxxxx xxxxxx xxxxxxxx xx xxxxxxx XX xxxxxxxx (XX) x. 1272/2008, xxxxx XXX nebude xxx xxxxxxx předložit xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx xxx x xxxxx 2-xxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (xxxxx XXX 111-76-2), pro třídu xxxxxxxxxxxxx „akutní toxicita (xxxxxxxxx)“ xxxx předloženy xxxx xxxxxxx poznatky, xx xxxxxxx vyplývá, xx xxxxxxxxxxx xxx xxxx xxxxx nebezpečnosti xxxxxxxxxxxx xx xxxxxxxxxx xxxxxx RAC, xxx xx xxxxxxx na xxxxxxxx xxxxxxx, nemusí xxx xxxxxx. Tato xxxxx xxxxxxxxxxxxx xx xxxxx xxxxxx xxx x příloze VI xxxxxxxx (XX) x. 1272/2008 xxxxxxx, dokud XXX xxxxxx xxx xxxxxxx xxxxxxxxx k xxxxx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx; xxxxxxx xxxxxxx třídy xxxxxxxxxxxxx, x xxxxxxx pojednává xxxxxxxxxx výboru XXX, xx zařazeny být xxxx.

(5)

Xxxxxxxx (ES) č. 1272/2008 xx xxxxx xxxx být xxxxxxxxxxxxx xxxxxxxx xxxxxxx.

(6)

Xxxxxxxxxx nových xxxx aktualizovaných harmonizovaných xxxxxxxxxxx xx xxxxxx xxx, x výhradou xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx potřebují určitou xxxx xx xx, xxx xxxxxxxxxxxx označování x xxxxxx xxxxx x směsí xxxxx xxxx xxxxxxxxxxx xxxxxxxxxxxx x xxxxxxx xxxxxxxxx xxxxxx. Xxxx doba xx xxxxxx xxxxxxxx x xxxx, xxx xxxxxxxxxx xxxx xxxxxxxx xxxx přijmout xxxxxxxx xxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx dalších xxxxxxxx xxxxxxxxx, které xxxxxxxx v xxxxxxxx xxxx provedených xxxxx xxxxxx xxxxxxxx. Xxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx stanovené v xx. 22 odst. 1 xxxx. f) xxxxxxxx Evropského xxxxxxxxxx x Xxxx (XX) x. 1907/2006&xxxx;(3) xxxx xxxxxxxxx xxxxxxxxx x xxxxxx 50 xxxxxxxx Xxxxxxxxxx parlamentu a Xxxx (EU) x. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx xx však xxxx být umožněno, xxx xxxxx xxxx xxxxxxxxxx týkající se xxxxxxxxxxx, xxxxxxxxxx x xxxxxx xxxxxxxxxx dobrovolně xxxxx xxxx xxxxxxxxxxxxx xxxxxx nařízení. To xx v xxxxxxx x přístupem xxxxx xx. 61 xxxx. 2 xxxxxxxx (ES) x. 1272/2008,

XXXXXXX XXXX XXXXXXXX:

Článek 1

Změny xxxxxxxx (XX) č. 1272/2008

Xxxxxxx 3 x xxxxx 3 xxxxxxx XX xxxxxxxx (XX) x. 1272/2008 xx mění x xxxxxxx x xxxxxxxx tohoto xxxxxxxx.

Xxxxxx 2

Vstup x xxxxxxxx x xxxxxxxxxxxx

Xxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx xxxx xx xxxxxxxxx x Xxxxxxx xxxxxxxx Evropské xxxx.

Xxxxxxx xx xxx xxx 1. xxxxxx 2022.

Xxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xxxxxx xxxxx xxx xxxxx x směsi klasifikovány, xxxxxxxxxx x xxxxxx x souladu s xxxxxxxxx (ES) x. 1272/2008 xx xxxxx xxxxxx xxxxxxxx ještě xxxxx xxxx 1. xxxxxx 2022.

Toto xxxxxxxx xx xxxxxxx x xxxxx xxxxxxx a přímo xxxxxxxxxx ve všech xxxxxxxxx xxxxxxx.

X Bruselu xxx 19. května 2020.

Xx Xxxxxx

Xxxxxx XXX XXX XXXXX

xxxxxxxxxxx

(1)&xxxx;&xxxx;xxxxXx. xxxx. X 353, 31.12.2008, x. 1.

(2)  Stanoviska xxxx xxxxxxxx xx xxxx xxxxxxxxxxx stránce: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/

(3)  Nařízení Xxxxxxxxxx xxxxxxxxxx a Xxxx (ES) č. 1907/2006 xx dne 18. xxxxxxxx 2006

x xxxxxxxxxx, xxxxxxxxx, povolování x omezování chemických xxxxx, o xxxxxxx Xxxxxxxx xxxxxxxx pro xxxxxxxx xxxxx, x xxxxx xxxxxxxx 1999/45/XX x x xxxxxxx xxxxxxxx Xxxx (XXX) x. 793/93, xxxxxxxx Xxxxxx (XX) č. 1488/94, směrnice Xxxx 76/769/XXX a směrnic Xxxxxx 91/155/XXX, 93/67/EHS, 93/105/XX x 2000/21/XX (Xx. xxxx. X 396, 30.12.2006, x. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (XX) x. 528/2012 xx xxx 22. xxxxxx 2012

x xxxxxxxx biocidních xxxxxxxxx xx xxx x jejich xxxxxxxxx

(Xx. xxxx. X 167, 27.6.2012, x. 1).

XXXXXXX

X příloze VI xxxxxxxx (XX) x. 1272/2008 xx xxxxxxx 3 x části 3 xxxx xxxxx:

1)

Xxxxxxxx xx xxxx xxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx faktory x XXX

Xxxxxxxx

Xxxx xxxx x xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx symbolů a xxxxxxxxxx slov

Kódy standardních xxx x xxxxxxxxxxxxx

Xxxx xxxxx. standardních xxx x xxxxxxxxxxxxx

„007-030-00-3

xxxxxxxx xxxxxxx …% [X ≤ 70 %]

231-714-2

7697-37-2.

Ox. Liq. 3

Xxxxx Xxx. 3

Skin Xxxx. 1 X

X272

X331

X314

XXX03

XXX06

XXX05

Xxx

X272

X331

X314

XXX071

Xx. Xxx. 3; X272: X ≥ 65 %

xxxxxxxxx: XXX = 2,65 mg/l (xxxx)

Xxxx Xxxx. 1 X; X314: C ≥ 20 %

Skin Corr. 1X; X314: 5 % ≤ C &xx; 20 %

X“

„014-048-00-5

xxxxxx x xxxxxxx xxxxxxx (x xxxxxxx < 3 μx, xxxxx &xx; 5 μx x x xxxxxxx xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Carc. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx

220-449-8

2768-02-7

Xxxx Xxxx. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„016-098-00-3

xxxxxxxx-xxxxxxxx

210-871-0

624-92-0

Xxxx. Liq. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 3

XXXX XX 3

XXXX SE 1

Xxx Xxxxx. 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X225

X331

X301

X336

X370 (horní xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X400

X410

XXX02

XXX06

XXX08

XXX09

Xxx

X225

X331

X301

X336

X370 (xxxxx xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: XXX = 5 xx/x (páry)

orální: XXX = 190 xx/xx XX

X = 1

X = 10“

„029-024-00-X

xxxxxxxxxxx xxx;

[xxxxx xxxxxx: xx 0,9 xx a xx 6,0 xx; xxxxx částic: od 0,494 xx 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Chronic 2

X411

XXX09

X411“

„029-025-00-5

xxx(X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)xxx;

xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxx;

[Xx-XXX]

239-703-4

312600-89-8

15627-09-5

Xxxx. Xxx. 1

Xxxxx Tox. 4

XXXX RE 2

Xxx Xxx. 1

Xxxxxxx Acute 1

Xxxxxxx Chronic 1

X228

X302

X373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (xxxxx)

X318

X410

xxxxxx: ATE = 360 mg/kg XX

X = 1

M = 1“

„050-031-00-9

xxxxxxxxxx-xxxxxxxx; [1]

stannan, xxxxxxx-, bis(koko acyloxy) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Xxxx. 1X

XXXX XX 1

X360X

X372 (xxxxxxxx xxxxxx)

XXX08

Xxx

X360X

X372 (imunitní systém)“

„601-092-00-0

dibenzo[def,p]chrysen;

dibenzo[a,l]pyren

205-886-4

191-30-0

Carc. 1X

Xxxx. 2

H350

H341

GHS08

Dgr

H350

H341

Carc. 1X; X350: X ≥ 0,001 %“

„603-237-00-3

xxxxxxxxx (ISO);

(1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyklopentanol

–

125225-28-7

115850-69-6

115937-89-8

Repr. 1X

Xxxxx Xxx. 4

XXXX XX 2

Aquatic Xxxxxxx 1

X360X

X302

X373 (oči, kůže, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (xxx, kůže, xxxxx)

X410

xxxxxx: XXX = 500 xx/xx XX

X = 100“

„603-238-00-9

xxx(2-(2-xxxxxxxxxxxxx)xxxxx)-xxxxx; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (XXX);

(2XX,3XX)-1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xx

–

76738-62-0

Xxxx. 2

Acute Xxx. 4

Xxxxx Tox. 4

Xxx Irrit. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: XXX = 3,13 xx/x (prach xxxx mlha)

orální: XXX = 490 mg/kg XX

X = 10

X = 10“

„603-240-00-X

2,2-bis(brommethyl)propan-1,3-diol

221-967-7

3296-90-0

Carc. 1X

Xxxx. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Sens. 1

H317

GHS07

Wng

H317“

„605-041-00-3

2-(4-terc-butylbenzyl)propanal

201-289-8

80-54-6

Repr. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (XXX);

X-xxxxx (4-chlor-2-methylfenoxy)ethanethioát; X-xxxxx 4-chlor-o-tolyloxythioacetát

246-831-4

25319-90-8

Acute Xxx. 4

XXXX XX. 2

Aquatic Xxxxx 1 Aquatic Xxxxxxx 1

X302

X373 (xxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxx)

X410

xxxxxx: ATE = 450 xx/xx TH

M = 10

X = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„607-741-00-4

4-{[(6-xxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xx; xxxxxxxxxxxxxx

–

951659-40-8

Xxxxx Xxx. 4

XXXX XX 2

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

H302

H373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: XXX = 500 xx/xx XX

X = 10

M = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (XXX);

xxxxxx-4-[(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxx

–

317815-83-1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

H400

H410

GHS09

Wng

H410

M = 1000

X = 1000“

„607-743-00-5

X-(+)-xxxxxx xxxxxxxx;

(2 X)-2-xxxxxxxxxxxxxxxx xxxxxxxx

201-196-2

79-33-4

Xxxx Xxxx. 1X

Xxx Xxx. 1

H314

H318

GHS05

Dgr

H314

EUH071“

„607-744-00-0

2-methoxyethylakrylát

221-499-3

3121-61-7

Flam. Liq. 3

Xxxx. 2

Repr. 1X

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Xxxx Corr. 1C

Eye Xxx. 1

Xxxx Xxxx. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: XXX = 2,7 xx/x (xxxx)

xxxxxx: XXX = 404 xx/xx XX“

„607-745-00-6

xxxxxxxxxx xxxxxxxx …%

206-058-5

298-12-4

Xxx Xxx. 1

Skin Xxxx. 1X

X318

X317

XXX05

XXX07

Xxx

X318

X317

X“

„607-746-00-1

xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx;

[xxxxxxxxxxx uvolněný x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]

274-357-8

70161-44-3

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

STOT SE 3

Xxxx Xxxxx. 2

Eye Xxxxx. 2

Xxxx Xxxx. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: XXX = 3 mg/l (xxxxx xxxx mlha)

orální: ATE = 1 100 mg/kg XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx xxxxxxxx;

xxxxxxxxxxxxxxxxxxxxxxx-1-xxxx, xxxxxxxx xxx;

[X-XXX]

–

66603-10-9

Xxxx. Xxx. 1

Acute Xxx. 3

XXXX RE 2

Xxxx Xxxxx. 2

Xxx Xxx. 1

Xxxxxxx Chronic 2

X228

X301

X373 (játra)

H315

H318

H411

GHS02

GHS06

GHS08

GHS05

GHS09

Dgr

H228

H301

H373 (xxxxx)

X315

X318

X411

xxxxxx: XXX = 136 xx/xx TH“

„612-294-00-3

mecetroniumetilsulfát;

N-ethyl-N,N-dimethylhexadekan-1-aminium-ethyl-sulfát;

mecetronium-ethyl-sulfát;

[MES]

221-106-5

3006-10-8

Skin Corr. 1

Xxx Xxx. 1

Aquatic Xxxxx 1

Aquatic Chronic 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

X = 1 000 “

„613-331-00-6

(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx;

xxxxxxxxxxxxxxxxxx

–

1417782-03-6

Xxxx Xxxx. 1

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

H317

H400

H410

GHS07

GHS09

Wng

H317

H410

M = 1

M = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (XXX);

1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxx

–

1003318-67-9

Xxxxxxx Xxxxxxx 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

xxxxxxxxx-xxxxx; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1X

Xxxxx Xxx. 2

Xxxxx Tox. 3

XXXX XX 1

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X360X

X330

X301

X372

X318

X400

X410

XXX08

XXX06

XXX05

XXX09

Xxx

X360X

X330

X301

X372

X318

X410

xxxxxxxxx: ATE = 0,14 mg/l (xxxxx xxxx mlha)

orální: XXX = 221 xx/xx XX

X = 1&xxxx;000

X = 10“

„613-334-00-2

xxxxxxxxxxxxxx (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1X

Xxxxx Xxx. 4

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: ATE = 500 xx/xx XX

X = 100

M = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [DCOIT]

264-843-8

64359-81-5

Acute Tox. 2

Xxxxx Xxx. 4

Xxxx Xxxx. 1

Xxx Xxx. 1

Xxxx Sens. 1 X

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X330

X302

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X302

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,16 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 567 xx/xx XX

Xxxx Irrit. 2; X315: 0,025 % ≤ X &xx; 5 %

Eye Xxxxx. 2; X319: 0,025 % ≤ X &xx; 3 %

Xxxx Xxxx. 1 X; X317: C ≥ 0,0015 %

X = 100

X = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Xxx. 4

Acute Xxx. 3

Xxxx Xxxx. 1X

Xxx Dam. 1

Xxxx Xxxx. 1 A

Aquatic Xxxxx 1

Aquatic Xxxxxxx 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: XXX = 1&xxxx;100 mg/kg XX

xxxxxx: XXX = 175 xx/xx XX

Xxxx Sens. 1 A; X317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(difluormethyl)-1-methyl-N-(3‘,4’,5’-trifluorbifenyl-2-yl)pyrazol-4-karboxamid;

fluxapyroxad

–

907204-31-3

Lact.

Aquatic Xxxxx 1

Aquatic Chronic 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

X = 1“

„616-230-00-5

X-(xxxxxxxxxxxxx)xxxxxxxxx; xxxxxxxxxxxxxxxxx; [XXX]

213-103-2

924-42-5

Xxxx. 1X

Xxxx. 1X

XXXX XX 1

X350

X340

X372 (xxxxxxxxx xxxxxxx xxxxxx)

XXX08

Xxx

X350

X340

X372 (xxxxxxxxx xxxxxxx xxxxxx)“

„616-231-00-0

5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxx; 2’-[(RS)-1,3-dimethylbutyl]-5-fluor-1,3-dimethylpyrazol-4-karboxanilid;

penflufen

–

494793-67-8

Carc. 2

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X351

X400

X410

XXX08

XXX09

Xxx

X351

X410

X = 1

X = 1“

„616-232-00-6

iprovalikarb (XXX);

xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxx

–

140923-17-7

Xxxx. 2

H351

GHS08

Wng

H351“

„616-233-00-1

silthiofam (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX RE 2

Aquatic Xxxxxxx 2

H373

H411

GHS08

GHS09

Wng

H373

H411“

„650-057-00-6

Margosa, xxxxxxx [xxxx lisovaný xx xxxxxxx xx xxxxx xxxxxxxx Xxxxxxxxxxx indica xxx xxxxxxxx, extrahovaný xxxxxxxxxxxxxx oxidem uhličitým]

283-644-7

84696-25-3

Aquatic Xxxxxxx 3

H412

H412“

2)

položky odpovídající xxxxxxxxx číslům 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 x 617–006–00-X xx nahrazují xxxxxx xxxxxxxxx:

Xxxxxxxx číslo

Chemický xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. limity, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx xxxx x xxxxxxxxx xxxxxxxxxxxxx

Xxxx standardních vět x xxxxxxxxxxxxx

Xxxx výstražných xxxxxxx x signálních xxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx doplň. xxxxxxxxxxxx xxx o xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx xxxxxxx …% [X &xx; 70 %]

231-714-2

7697-37-2

Xx. Xxx. 2

Xxxxx Xxx. 1

Xxxx Xxxx. 1 X

X272

X330

X314

XXX03

XXX06

XXX05

Xxx

X272

X330

X314

XXX071

Xx. Xxx. 2; X272: X ≥ 99 %

Xx. Xxx. 3; X272: 70 % ≤ X &xx; 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

X361x ***

X410

XXX08

XXX09

Xxx

X361x ***

H410

M = 10“

„015-134-00-5

pirimifos-methyl (ISO);

O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforothioát

249-528-5

29232-93-7

Acute Xxx. 4

XXXX RE 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X302

X372 (xxxxxxx xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (xxxxxxx xxxxxx)

X410

xxxxxx: XXX = 1&xxxx;414 xx/xx XX

X = 1&xxxx;000

X = 1&xxxx;000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Xxx 1

Xxxxx. Xxx

Xxxxx Xxx. 1

Xxxx Xxxx. 1X

Xxxxxxx Xxxxx 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (xxxxx)

X“

„050-021-00-4

xxxxxxxxxxxxxxxxxxxxx

222-583-2

3542-36-7

Xxxx. 1X

Xxxxx Xxx. 2

STOT XX 1

Xxxxxxx Xxxxxxx 3

H360D

H330

H372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

X412

Xxxx. 1B; X360 X: X ≥ 0,03 %

xxxxxxxxx: XXX = 0.098 xx/X (prach xxxx xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxxxxxxxxxx; [XXXX]

239-622-4

15571-58-1

Xxxx. 1X

XXXX RE 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X360X

X372 (imunitní systém)

H400

H410

GHS08

GHS09

Dgr

H360D

H372 (xxxxxxxx xxxxxx)

X410“

„082-013-00-1

xxxxxxx prášek; [xxxxxx xxxxxx &xx; 1 xx]

231-100-4

7439-92-1

Xxxx. 1 X

Xxxx.

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360XX

X362

X400

X410

XXX08

XXX09

Xxx

X360XX X362

X410

Xxxx. 1 X; X360X: X ≥ 0,03 %

X = 1

M = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Xxx. 4*

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: XXX = 1&xxxx;200 xx/xx TH“

„603-065-00-9

m-bis(2,3-epoxypropoxy)benzen;

resorcinoldiglycidylether

202-987-5

101-90-6

Carc. 1X

Xxxx. 2

Xxxxx Xxx. 3

Xxxxx Tox. 4

Xxxx Xxxxx. 2

Eye Xxxxx. 2

Xxxx Sens. 1

Xxxxxxx Xxxxxxx 3

X350

X341

X311

X302

X315

X319

X317

X412

XXX08

XXX06

Xxx

X350

X341

X311

X302

X315

X319

X317

X412

xxxxxxxx: ATE = 300 mg/kg XX xxxxxx: XXX = 500 mg/kg XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (ISO);

methyl-2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoát

401-190-1

101200-48-0

STOT XX 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

X = 100“

„607-256-00-8

xxxxxxxxxxxx (XXX);

xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Tox. 3

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (prach xxxx xxxx)

X = 10

X = 10“

„607-314-00-2

ethofumesát (XXX);

(XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„609-041-00-4

2,4-dinitrofenol

200-087-7

51-28-5

Acute Xxx. 3 *

Xxxxx Xxx. 3

Xxxxx Xxx. 2

XXXX XX 1

Xxxxxxx Xxxxx 1

X331

X311

X300

X372

X400

XXX06

XXX08

XXX09

Xxx

X331

X311

X300

X372

X400

xxxxxxxx: ATE = 300 xx/xx XX orální: XXX = 30 xx/xx XX“

„609-064-00-X

xxxxxxxxx (ISO);

2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyklohexandion

–

104206-82-8

Repr. 2

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

H361d

H373 (xxx, xxxxxxx systém)

H400

H410

GHS08

GHS09

Wng

H361d

H373 (xxx, xxxxxxx xxxxxx)

X410

X = 10

X = 10“

„613-112-00-5

xxxxxxxxxx (XXX);

2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXX]

247-761-7

26530-20-1

Xxxxx Xxx. 2

Xxxxx Tox. 3

Xxxxx Xxx. 3

Skin Xxxx. 1

Xxx Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1

X330

X311

X301

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X311

X301

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,27 xx/x (prach nebo xxxx)

xxxxxxxx: XXX = 311 mg/kg XX xxxxxx: ATE = 125 xx/xx TH

Skin Xxxx. 1 X; X317: X ≥ 0,0015 %

X = 100

X = 100“

„613-115-00-1

xxxxxxxxx (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Xxxxx Tox. 4

Xxx Dam. 1

Xxxx Xxxx. 1

Aquatic Xxxxxxx 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: XXX = 1&xxxx;600 mg/kg TH“

„613-125-00-6

hexythiazox (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„613-202-00-4

pymetrozin (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

H351

H361fd

H410

GHS08

GHS09

Wng

H351

H361fd

H410

M = 1“

„613-259-00-5

xxxxxxxxxxx (XXX);

xxxxxxx xxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxx

428-790-6

72963-72-5

Xxxx. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X332

X302

X371 (xxxxxxx xxxxxx; xxxxxx, xxxxxxxxx)

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X332

X302

X371 (nervový xxxxxx; orální, inhalační)

H410

inhalační: XXX = 1,4 xx/x (prach xxxx xxxx)

xxxxxx: ATE = 550 mg/kg XX

X = 10

X = 10“

„616-014-00-0

xxxxx-xx-xxxx; xxxxxxxxxxxxxxxxxx, ethyl(methyl)ketonoxim

202-496-6

96-29-7

Carc. 1X

Xxxxx Xxx. 4

Acute Xxx. 3

XXXX XX 3

XXXX XX 1

XXXX XX 2

Xxxx Xxxxx. 2

Xxx Xxx. 1

Xxxx Xxxx. 1

X350

X312

X301

X336

X370 (xxxxx xxxxxxx cesty)

H373 (krevní xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (xxxxx dýchací xxxxx)

X373 (krevní xxxx)

X315

X318

X317

xxxxxxxx: XXX = 1&xxxx;100 xx/xx XX orální: XXX = 100 xx/xx XX“

„617-006-00-X

xxx(α,α-xxxxxxxxxxxxxx)xxxxxxx

201-279-3

80-43-3

Xxx. Xxxxx. X

Xxxx. 1X

Xxxx Irrit. 2

Xxx Irrit. 2

Xxxxxxx Xxxxxxx 2

X242

X360X

X315

X319

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X242

X360X

X315

X319

X411“

3)

xxxxxxx odpovídající xxxxxxxxx číslům 601-064-00-8 x 607-693-00-4 xx xxxxxxx.